ライフサイエンスコーパス: anti-CCP antibody

1 the subset of African American patients with anti-CCP antibodies.

2 igher titers of autoantibodies, particularly anti-CCP antibodies.

3 ve patients with polyarticular-onset JRA had anti-CCP antibodies.

4 ted with presence of the SE independently of anti-CCP antibodies.

5 isotypes, anti-cyclic citrullinated peptide (anti-CCP) antibodies, 14 cytokines and chemokines (by be

6 sociation of the SE with the presence of the anti-CCP antibody: 86 (48.9%) of 176 patients with anti-

7 esence, development, and extent of erosions, anti-CCP antibodies alone are not a sufficiently accurat

8 Concordance rates for anti-CCP antibodies among ASPs were statistically signif

9 on models were fitted to test the ability of anti-CCP antibodies and RF to predict erosions.

10 Ps, and 688 healthy children were tested for anti-CCP antibodies and RF.

11 e sibling had significantly higher titers of anti-CCP antibodies and were more likely to be SE positi

12 egative likelihood ratios from 37 studies of anti-CCP antibody and 50 studies of RF.

13 0 participants and that examined the role of anti-CCP antibody and RF in the diagnosis or prognosis o

14 ested for anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-mycobacterial Hsp65 antibo

15 levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and current use of biologic agents,

16 of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies and HLA-DRB1 genotyping, a panel of

17 antibody, anti-cyclic citrullinated peptide (anti-CCP) antibody, and rheumatoid factor.

18 in children with polyarticular JRA, whether anti-CCP antibodies are associated with clinical feature

19 Our objectives were to determine whether anti-CCP antibodies are associated with HLA-DR4 in child

20 Anti-CCP antibodies are more specific than RF for diagno

21 Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a stronger predictor of the sev

22 The presence of anti-CCP antibodies at baseline was strongly associated

23 s strongly associated with the production of anti-CCP antibodies, but not RF.

24 All patients were tested for anti-CCP antibodies (by enzyme-linked immunosorbent assa

25 titers of anti-cyclic citrullinated peptide (anti-CCP) antibodies compared with female patients, even

26 A and 2% of the other JRA patients exhibited anti-CCP antibodies, compared with only 0.6% of the cont

27 s, the levels of IgA-RF, IgG-RF, and IgG and anti-CCP antibodies decreased significantly more than di

28 h anti-CCP- disease and with lower levels of anti-CCP antibodies, even when controlling for the SE.

29 These data demonstrate increased anti-CCP antibody formation in HLA-DR4-positive patients

30 Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been detected in patients with

31 were to examine the role of baseline RF and anti-CCP antibodies in determining the likelihood of pat

32 Anti-CCP antibodies in JRA are associated with polyartic

33 The overall prevalence of anti-CCP antibodies in JRA is low, but a substantial pro

34 els were investigated to examine the role of anti-CCP antibodies in patients stratified by RF status.

35 (hsCRP), anti-cyclic citrullinated peptide (anti-CCP) antibodies, interleukin-6 (IL-6), and soluble

36 However, the combination of SE, smoking, and anti-CCP antibodies is associated with a high risk of pr

37 The combined associations of anti-CCP antibody level and biologic agent use with myoc

38 2%) experienced a > or =25% reduction in the anti-CCP antibody level during the course of treatment,

39 After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration

40 appear to be associated with declines in the anti-CCP antibody level.

41 isease duration predicts greater declines in anti-CCP antibody levels with treatment in RA.

42 ompared with 36 (32.7%) of 110 patients with anti-CCP antibody-negative RA (P = 0.01, by chi-square t

43 A directly correlated with the levels of the anti-CCP antibodies, of the Th1/Th17 cytokines, and of t

44 radiologic damage, and to determine whether anti-CCP antibodies or RF is sufficiently robust to be c

45 ly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no assoc

46 CP antibody: 86 (48.9%) of 176 patients with anti-CCP antibody-positive RA had at least 1 SE allele,

47 or radiographic progression was greater with anti-CCP antibody positivity than with IgM RF positivity

48 Knowledge of anti-CCP antibody status is most informative in RF-negat

49 f association of these genotypes with RF and anti-CCP antibody status suggests that they act downstre

50 to their anti-cyclic citrullinated peptide (anti-CCP) antibody status, was performed.

51 ctor, and anti-cyclic citrullinated peptide (anti-CCP) antibody testing.

52 articular-onset JRA were more likely to have anti-CCP antibodies than were those without HLA-DR4 alle

53 sex, age, anti-cyclic citrullinated peptide (anti-CCP) antibody titer, disease duration, and C-reacti

54 f the SE did not fully explain the increased anti-CCP antibody titers observed in these families.

55 , and IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies together with an elevated C-reactiv

56 elevated level of any RF isotype and/or IgG anti-CCP antibodies was further associated with an enhan

57 An interaction of smoking, SE alleles, and anti-CCP antibodies was observed and was associated with

58 Anti-CCP antibodies were associated with polyarticular o

59 positive and negative likelihood ratios for anti-CCP antibody were 67% (95% CI, 62% to 72%), 95% (CI

60 ssociated with seropositivity for RF and the anti-CCP antibody, which was highly relevant given the a